Last edition
News about "Biologics CMO business"
Aurobindo Pharma's China Manufacturing Plant to Reach EBITDA Break-Even by Q3 FY26
The facility began operations in late November 2024 and is currently ramping up production. With an initial annual capacity exceeding two billion units, it has already started production and invoicing between Q4 FY25 and Q1 FY26. The company has invested approximately USD 145 million in setting up the plant.
Biologics CMO Business | 18/08/2025 | By Darshana | 205
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members